Tinlarebant (LBS-008)
Geographic Atrophy (Dry AMD)
Key Facts
About Belite Bio
Belite Bio is a publicly traded clinical-stage biopharmaceutical company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. Their lead candidate Tinlarebant, developed from their proprietary RBP4 IP portfolio, is currently in multiple Phase 3 trials for Geographic Atrophy and Stargardt disease, with breakthrough therapy and orphan drug designations. The company has expanded their pipeline to include treatments for liver disease and diabetes, leveraging their core RBP4 platform technology.
View full company profileAbout Belite Bio
Belite Bio is a publicly traded clinical-stage biopharmaceutical company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. Their lead candidate Tinlarebant, developed from their proprietary RBP4 IP portfolio, is currently in multiple Phase 3 trials for Geographic Atrophy and Stargardt disease, with breakthrough therapy and orphan drug designations. The company has expanded their pipeline to include treatments for liver disease and diabetes, leveraging their core RBP4 platform technology.
View full company profileAbout Belite Bio
Belite Bio is a publicly traded clinical-stage biopharmaceutical company focused on advancing novel therapeutics for retinal degenerative eye diseases with significant unmet medical needs. Their lead candidate Tinlarebant, developed from their proprietary RBP4 IP portfolio, is currently in multiple Phase 3 trials for Geographic Atrophy and Stargardt disease, with breakthrough therapy and orphan drug designations. The company has expanded their pipeline to include treatments for liver disease and diabetes, leveraging their core RBP4 platform technology.
View full company profile